Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharma company, will participate in the Life Sciences Investor Forum on June 24-25, 2026.
CEO Robert Bitterman will present the INTASYL gene-silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by live Q&A and one-on-one meetings.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PHIO
On the day this news was published, PHIO declined 2.31%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
PHIO was up about 1.9% ahead of this investor-forum news, while at least three biotech peers in the momentum scanner were moving down together, indicating stock-specific action rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 26 | Investor roadshow | Positive | -0.9% | Renmark virtual non-deal roadshow highlighting INTASYL platform and PH-762. |
| May 12 | Fireside chat | Positive | +1.9% | Force Family Office chat discussing Phase 1b PH-762 data and cash runway. |
| May 07 | Q1 2026 earnings | Neutral | -6.1% | Quarterly results with higher R&D spend and business update on PH-762. |
| Apr 23 | Investor roadshow | Positive | -1.6% | Renmark virtual roadshow covering INTASYL platform and PH-762 progress. |
| Apr 13 | Fireside chat | Positive | +2.5% | Force Family Office chat on INTASYL and PH-762 Phase 1b skin cancer data. |
Recent outreach and update events have produced mixed reactions, with a slight tilt toward negative price moves after news.
Regulatory & Risk Context
Reported short interest reflects relatively low short positioning, suggesting more limited short-squeeze potential and a moderate contribution to trading volatility.
An effective S-3 resale shelf allows warrant holders to resell up to 11,763,800 shares; Phio would receive cash only upon warrant exercise, which could support PH-762 development and working capital.
Market Pulse Summary
This announcement extends PHIO’s investor outreach, showcasing the INTASYL platform and PH-762 at a virtual forum. With prior events drawing mixed market responses, investors may watch for substantive clinical or regulatory updates beyond this June 25 presentation.
Key Terms
sirna medical
immuno-oncology medical
cutaneous carcinomas medical
AI-generated analysis. Not financial advice.
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetings
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will conclude with a live question and answer session, providing attendees the opportunity to engage directly. In addition, Mr. Bitterman will be available for one-on-one meetings on June 24-25, 2026.
"We look forward to participating in the Life Sciences Investor Forum, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
One-on-One Meetings: Phio's availability is June 24-25, 2026
Phio's Presentation and live Q&A : Thursday June 25, 2026, at 3 PM EDT
REGISTER HERE: Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
For additional information, visit the Company's website www.virtualinvestorconferences.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Virtual Investor Conferences
Greg Young: greg@otcmarkets.com
VP Corporate Services, Investor Access
OTC Markets Group
(212) 652-5958
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301860